Latest news

Regulatory

FDA Expands Casgevy Approval to Children Aged 2 With Sickle Cell Disease and Beta Thalassemia

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Casgevy, allowing children as young as...
Commercial

In its biggest-ever transaction, Vertex pays $10 billion to buy endocrine disease expert Crinetics

Vertex Pharmaceuticals is making its biggest-ever acquisition to date, to the tune of $10 billion, of Crinetics Pharmaceuticals. While...
Clinical

Phase 3 KRYSTAL-10 Study Fails to Meet Primary Endpoints for Krazati in Metastatic Colorectal Cancer

Bristol Myers Squibb has disclosed detailed results from the phase 3 KRYSTAL-10 trial evaluating Krazati (adagrasib) in combination with...
Clinical

Kailera and Hengrui Report Phase 3 Results for Oral GLP-1 Drug in Obesity and Type 2 Diabetes

Kailera Therapeutics and its partner Jiangsu Hengrui Pharmaceutical reported that the oral GLP-1 receptor agonist HRS-7535 met the primary...
Insights

Top 10 Reasons Precision Medicine Requires Better Data Integration

Executive Summary Precision medicine is transforming healthcare by shifting treatment...
Insights

Why Pharma Supply Chains Need a Resilience-First Strategy

Executive Summary For decades, pharmaceutical supply chains were primarily designed...
Commercial

Orca Bio Gets FDA Green Light For Tregzi; IPO a Real Possibility

Orca Bio has officially entered the commercial marketplace after securing the FDA nod for Tregzi, the first engineered cell...
Commercial

Ipsen to Acquire Memo and Phase 2 BKPyV Antibody Potravitug in Deal Worth Up to €700 Million

French pharmaceutical company Ipsen has agreed to acquire Switzerland-based Memo Therapeutics and its lead rare disease candidate potravitug in...
Clinical

BridgeBio Advances Attruby Launch and Three Late-Stage Drug Programs as It Secures New Investment

BridgeBio Pharma is continuing the launch of Attruby while advancing three drug candidates that could potentially reach the market...
Clinical

Corxel Ready to Make Waves Worldwide After Positive Oral GLP-1 Phase 2 Results

Less than six months after securing hundreds of millions...
Insights

Top 10 Real-World Use Cases for AI in Clinical Development

Executive Summary Artificial intelligence is rapidly becoming one of the...
Insights

Why Medical Affairs Teams Need New Skills for the Next Decade

Executive Summary Medical affairs has become one of the fastest-evolving functions in the pharmaceutical industry. Traditionally, medical affairs organizations focused on...
Regulatory

Viridian Therapeutics’ Lumvoa Gets FDA Nod For Thyroid Eye Disease Treatment

Viridian Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa for the treatment of thyroid...
Commercial

Zymeworks to Acquire Theravance in $929 Million Deal

Zymeworks has agreed to acquire Theravance in a transaction valued at approximately $929 million, adding Theravance’s commercial products, royalty...
Commercial

Roche buys Point-of-Care Technology Platform from LumiraDx

Swiss pharmaceutical company Roche announced its agreement to acquire...
Commercial

Scorpion Secures $150M in Series C Funding to Expand Cancer Pipeline Clinical Plans

Scorpion Therapeutics has raised $150M to strengthen its clinical...

Popular

Most popular life news you must read today

View all articles

Commercial

Information Technology

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Alnylam has entered into a partnership with the scientist instrumental in developing the technology...
Editorial Team -

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

Chugai Pharmaceutical has entered into a research collaboration with Singapore-based Gero to develop antibody-based...
Editorial Team -

J&J MedTech presents the first Ottava surgical robot clinical cases

Johnson & Johnson MedTech successfully conducted the initial clinical use of Ottava surgical robot...
Editorial Team -

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

Common conditions in women such as PCOS, menopause, and endometriosis often lead to hormonal...
Editorial Team -

Regulatory

Commercial

In its biggest-ever transaction, Vertex pays $10 billion to buy endocrine disease expert Crinetics

Vertex Pharmaceuticals is making its biggest-ever acquisition to date,...
Clinical

Phase 3 KRYSTAL-10 Study Fails to Meet Primary Endpoints for Krazati in Metastatic Colorectal Cancer

Bristol Myers Squibb has disclosed detailed results from the...
Clinical

Kailera and Hengrui Report Phase 3 Results for Oral GLP-1 Drug in Obesity and Type 2 Diabetes

Kailera Therapeutics and its partner Jiangsu Hengrui Pharmaceutical reported...
Clinical

Phase 3 NSCLC study for Pfizer’s first novel ADC from the acquisition of Seagen fails

The big gamble that Pfizer made on antibody-drug conjugates...

Research & Development

Market Access

Manufacturing

UCB to Build $2 Billion Biologics Manufacturing Facility in Georgia

Belgium-based UCB has announced plans to invest $2 billion...
Manufacturing

Viatris to Cut 10% of Workforce Following Strategic Review and Reports Fire at India Plant

Viatris has outlined plans to reduce its global workforce...

Manufacturing & RegulatoryPOPULAR
Find Your Perfect Music Festival